S-1: Tivic Health Systems Eyes Expansion with Proposed Common Stock and Warrant Offering

Tivic Health Systems is seeking to raise capital through a best efforts offering of common stock and warrants to fund working capital and general corporate purposes.

Summary

• Tivic Health Systems is planning a best efforts offering consisting of common stock and common warrants, along with pre-funded warrants for certain investors.
• The offering aims to raise capital for working capital and general corporate purposes.
• The company has engaged Maxim Group LLC as the exclusive placement agent.
• The securities are expected to be issued in a single closing, with delivery versus payment upon receipt of investor funds.
• The offering includes common warrants with an exercise price to be determined, exercisable upon issuance and expiring five years from issuance.
• Pre-funded warrants are offered as an alternative to common stock for investors who would exceed beneficial ownership thresholds.
• The company's common stock is listed on the Nasdaq Capital Market under the symbol TIVC.
• The last reported sale price of TIVC on March 22, 2024 was $1.39 per share.
• The company is an emerging growth company and a smaller reporting company, which allows for reduced reporting requirements.

Sentiment

Score: 5

Explanation: The document is neutral. It describes a capital raising activity, but also highlights the company's financial challenges and risks.

Positives

• The offering provides capital for working capital and general corporate purposes.
• The company has engaged Maxim Group LLC as the exclusive placement agent.
• The company is an emerging growth company and a smaller reporting company, which allows for reduced reporting requirements.

Negatives

• The offering is on a best efforts basis, meaning there is no guarantee that all securities will be sold.
• Investors will experience immediate and substantial dilution in the net tangible book value per share.
• There is no established trading market for the offered Common Warrants or Pre-Funded Warrants.
• The company's management will have broad discretion over the use of the net proceeds from this offering.

Risks

• The company's cash and financial resources may be insufficient to meet its anticipated needs for the next twelve months, which raises substantial doubt about its ability to continue as a going concern.
• The company has identified a material weakness in its internal control over financial reporting associated with staffing levels, which is common for the stage and size of the Company.
• The company may not raise the amount of capital it believes is required for its business plans.
• Resales of the company's shares of common stock in the public market by investors in this offering may cause the market price of its shares of common stock to fall.
• There is no public market for the Pre-Funded Warrants or the Common Warrants being offered in this offering.

Future Outlook

The company expects to incur substantial additional operating losses for the foreseeable future to expand its markets, complete development of new products, obtain regulatory approvals, launch and commercialize its products and continue research and development programs.

Industry Context

The document mentions that bioelectronic medicine is a branch of the global neuromodulation market, which is growing. IDTechEx forecasts peripheral nerve stimulation to grow at a 35% CAGR from 2019 through 2029.

Stakeholder Impact

• Shareholders will experience dilution as a result of the offering.
• The company's ability to execute its business plan will be impacted by the success of the offering.
• The company's employees will be impacted by the company's ability to fund its operations and continue its research and development programs.

Next Steps

• The company will determine the final offering price and other terms of the offering.
• The company will seek to complete the offering and receive net proceeds for working capital and general corporate purposes.
• The company will continue to monitor and evaluate options to add complementary product opportunities into its product portfolio.

Key Dates

Keywords

common stock, warrants, offering, Tivic Health, capital raise, Maxim Group, pre-funded warrants, best efforts, placement agent, TIVC